4 drug(s) with this reaction
4,124 total reports
Foetal Exposure During Pregnancy has been reported as an adverse reaction across 4 drug(s) manufactured by Abbvie Inc in the FDA Adverse Event Reporting System (FAERS) database. A combined total of 4,124 adverse event reports mention foetal exposure during pregnancy in connection with Abbvie Inc products.
This page provides a breakdown of which Abbvie Inc drugs are most commonly associated with foetal exposure during pregnancy, along with report counts and links to detailed safety analyses for each medication. Understanding which drugs from a single manufacturer share a common adverse reaction can help patients and healthcare providers identify potential class-wide safety patterns.
The following Abbvie Inc drugs have foetal exposure during pregnancy listed in their FDA adverse event reports, sorted by report count:
In addition to foetal exposure during pregnancy, the following adverse reactions have been reported across Abbvie Inc's drug portfolio:
4 drug(s) manufactured by Abbvie Inc have foetal exposure during pregnancy listed in their FDA adverse event reports: RITONAVIR, DIVALPROEX SODIUM, LOPINAVIR AND RITONAVIR, SEVOFLURANE.
There are a combined 4,124 reports of foetal exposure during pregnancy across 4 Abbvie Inc drug(s) in the FDA adverse event database.